Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07445074 · ClinicalTrials.gov registry record · NA

AI-Based Mobile Intervention on Medication Non-Adherence and Transition

A NA study of Epilepsy and Seizure, sponsored by University of Central Florida.

Recruiting
Registry status
NA
Development phase
200
Enrollment target
1
Study location

NCT07445074 is a NA study of Epilepsy and Seizure that is actively recruiting participants, run by University of Central Florida. The registered enrollment target is 200 participants, below the 951-participant average among 160 other Epilepsy trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07445074, a NA study of Epilepsy and Seizure, is actively recruiting participants, sponsored by University of Central Florida.

RECRUITING
Registry status
NA
Development phase
200 participants
Enrollment target
1
Study location

Study Summary

This study aims to examine whether the AI-personalized version of the Medilepsy® app is more effective than the non-AI (standard version without AI personalization) can improve key outcomes, such as medical adherence and transition readiness, among underserved adolescents and young adults with epilepsy, ages 14-24, in Florida, USA. Outcomes are organized into primary (effectiveness), secondary (usability), and exploratory (language experience) endpoints.

Conditions Studied

Interventions

  • OTHER Medilepsy® Chatbot AI-Enhanced
  • OTHER Medilepsy® Chatbot Standard

Study Locations (1)

Florida

  • University of Central Florida - Orlando

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2026-03
Est. Completion 2026-12
Phase NA

Sponsor

University of Central Florida

91 total trials

What the Registry Record Tells You About NCT07445074

The ClinicalTrials.gov registry entry for NCT07445074 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 951-participant average among 160 other Epilepsy trials with a reported enrollment target (79% lower). The listed sponsor is University of Central Florida, which has 91 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Epilepsy appearing as the primary indexed condition, and to 2 interventions - of which Medilepsy® Chatbot AI-Enhanced is the first listed.

NCT07445074 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT07445074 about?

NCT07445074 is a clinical study titled "AI-Based Mobile Intervention on Medication Non-Adherence and Transition". This study aims to examine whether the AI-personalized version of the Medilepsy® app is more effective than the non-AI (standard version without AI personalization) can improve key outcomes, such as medical adherence and transition readiness, among underserved adolescents and young adults with epile...

What is the current status of trial NCT07445074?

This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2026-03. Estimated completion is 2026-12.

What conditions does trial NCT07445074 study?

This clinical trial studies the following conditions: Epilepsy, Seizure.

What interventions are being tested in trial NCT07445074?

The interventions under investigation include: Medilepsy® Chatbot AI-Enhanced (OTHER), Medilepsy® Chatbot Standard (OTHER).

Who is sponsoring clinical trial NCT07445074?

This trial is sponsored by University of Central Florida, which has 91 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07445074 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Epilepsy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.